Ordering
Available Variants5 mg
CHA.61588-5mg
Price
€82.28
Available – Dispatch in 14 days
25 mg
CHA.61588-25mg
Price
€331.84
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.61588-5mg | €82.28 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.61588-25mg | €331.84 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C23H19N3O3S2 |
|---|---|
| CAS Number | 313254-51-2 |
| Molecular Weight | 449.55 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302,H319,H413 |
| pcodes | P273 - P301 + P312 + P330 - P305 + P351 + P338 |
| Hazard Classifications | Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
ICA-121431, also known by its CAS number 313254-51-2, is a potent and selective inhibitor of the Nav1.5 sodium channel. This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of atrial fibrillation and other cardiac arrhythmias. ICA-121431 exhibits a high degree of specificity for the Nav1.5 channel, which is predominantly expressed in the heart, allowing for targeted modulation of cardiac sodium channel activity. The compounds mechanism of action involves binding to the channel, thereby reducing sodium influx and subsequent cardiac excitability. As a result, ICA-121431 has shown promise in preclinical studies as a potential anti-arrhythmic agent, with a favorable pharmacokinetic and safety profile, warranting further investigation into its clinical efficacy and potential as a novel therapeutic agent for the management of cardiac arrhythmias.
